KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Depreciation & Amortization (CF) (2018 - 2025)

Vir Biotechnology's Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed 0.42% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $11.7 million, down 19.77%, while the annual FY2025 figure was $11.7 million, 19.77% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $2.9 million at Vir Biotechnology, down from $3.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $5.6 million in Q1 2023 and bottomed at $1.3 million in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $2.9 million (2024), against an average of $2.9 million.
  • The largest annual shift saw Depreciation & Amortization (CF) surged 302.71% in 2023 before it crashed 36.53% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.4 million in 2021, then soared by 69.57% to $2.4 million in 2022, then soared by 90.43% to $4.5 million in 2023, then plummeted by 35.57% to $2.9 million in 2024, then increased by 0.42% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Depreciation & Amortization (CF) are $2.9 million (Q4 2025), $3.0 million (Q3 2025), and $2.9 million (Q2 2025).